Back to search results

CPAP, Eszopiclone, and Obstructive Sleep Apnea Study

This study is looking at how a medication called eszopiclone might help people with obstructive sleep apnea (OSA) use their CPAP machine more consistently and improve their thinking skills. Researchers believe that by changing how easily you wake up during sleep (your arousal threshold), eszopiclone could make CPAP therapy more effective. You might be able to join if you are 18 or older and have a new diagnosis of OSA, meaning you have at least 10 breathing pauses per hour during sleep. The study will measure how well you stick to CPAP daily for three months and check your attention and control at the beginning and at 1, 2, and 3 months. The study aims to enroll 250 participants, but its current status is unclear.

Study design
This is a randomized, controlled clinical trial, meaning participants will be assigned by chance to receive either eszopiclone or a placebo. It plans to include 250 participants.
What's involved
You would take either eszopiclone or a placebo. Your CPAP adherence will be measured daily for three months, and you will complete attention tests at baseline and at 1, 2, and 3 months.
Compensation
Not stated in the trial record.
Follow-up
Your CPAP adherence will be measured daily over 3 months, and cognitive tests will be performed at 1, 2, and 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07332442

Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea

Recruiting
PHASE3Ages 18+InterventionalBasic science
Yale University
~250 participants
Updated 2026-06-03 on ClinicalTrials.gov
What's tested:EszopiclonePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
CPAP adherence
Measured over Daily over 3 months
+1 more outcome measured

Conditions

Sleep Apnea
Obstructive Sleep Apnea

Explore related trials

Obstructive Sleep Apnea

Where it's being run

1 sites across 1 states
Connecticut1

Study leadership

  • Audrey Zinchuk,, MD, MHS · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Andrey Zinchuk, MD, MHS
[email protected]
475-655-6199
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to provide informed consent.
Clinically confirmed new diagnosis of OSA:

Exclusion

Known non-OSA related conditions associated with sleep-disordered breathing (e.g., a central disorder of hypersomnolence, neurological, neuromuscular, or pulmonary disorder)
Use of sleep-inducing medications (e.g., other non-benzodiazepine sedative hypnotic-drugs \[e.g., zoldpidem\], benzodiazepines, non-selective antihistamines, trazodone, opiates, barbituates)
Known hypersensitivity reaction to eszopiclone
Contraindications to its use based on medical history or function (e.g., dizziness at baseline or established mobility problems or imbalance)
History of complex sleep behaviors (e.g., NREM or REM parasomnias)
Concomitant use of ≥ 2 servings of alcohol per night or other CNS depressant for 2 weeks prior or throughout the study
Sleep opportunity of less than 7 hours
Severe active depression or other mental health disorders (e.g., schizophrenia, bipolar disorder, personality disorder).
History of sleep-walking, sleep-driving, and engaging in other activities while not fully awake
History of motor vehicle accidents related to sleepiness and/or motor vehicle "near misses" (e.g. sleepiness during driving or lane changes)
Severe hepatic impairment (liver function tests 2 X the upper limit of normal)
Unstable medical condition (e.g., decompensated heart failure, end-stage chronic obstructive pulmonary disease, end-stage renal disease)
Females of childbearing potential who are pregnant, breastfeeding, or intend to become pregnant, and women who are in the process of egg donation .

What this trial measures

  • CPAP adherenceDaily over 3 months

    Mean daily average of CPAP use over 3 months

  • Flanker inhibitory control and attention testBaseline, 1-, 2- and 3-months

    Executive function is assessed using the validated NIH Toolbox Cognition Battery's Flanker inhibitory control and attention test. In a Flanker task, participants are required to indicate the left-right orientation of a centrally presented stimulus while inhibiting attention to the potentially incongruent stimuli that surround it (i.e., the flankers, typically two on either side). Primary outcome is the overall percent of correct responses in incongruent trials.